Compare CLRO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLRO | QNRX |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 14.5M |
| IPO Year | 2018 | 2023 |
| Metric | CLRO | QNRX |
|---|---|---|
| Price | $5.26 | $8.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 27.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $0.29 | $0.21 |
| 52 Week High | $15.42 | $41.80 |
| Indicator | CLRO | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 48.09 |
| Support Level | $6.10 | $7.13 |
| Resistance Level | $6.49 | $10.44 |
| Average True Range (ATR) | 0.38 | 0.74 |
| MACD | -0.09 | 0.38 |
| Stochastic Oscillator | 0.00 | 60.76 |
ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.